UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.64
-0.07 (-0.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
UroGen Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 89.36 | 82.71 | 64.36 | 48.04 | 11.8 | 0.02 | Upgrade
|
| Revenue Growth (YoY) | 15.64% | 28.52% | 33.96% | 307.17% | 65450.00% | -98.40% | Upgrade
|
| Cost of Revenue | 8.7 | 9.36 | 7.65 | 5.16 | 1.01 | - | Upgrade
|
| Gross Profit | 80.67 | 73.35 | 56.7 | 42.89 | 10.79 | 0.02 | Upgrade
|
| Selling, General & Admin | 110.85 | 93.27 | 82.84 | 87.54 | 90.22 | 60.2 | Upgrade
|
| Research & Development | 53.55 | 45.61 | 52.91 | 47.64 | 40.71 | 49.3 | Upgrade
|
| Operating Expenses | 164.4 | 138.89 | 135.74 | 135.18 | 130.93 | 109.5 | Upgrade
|
| Operating Income | -83.73 | -65.54 | -79.04 | -92.29 | -120.14 | -109.48 | Upgrade
|
| Interest Expense | -12.22 | -14.72 | -8.44 | - | - | - | Upgrade
|
| Interest & Investment Income | 6.82 | 2.64 | 0.94 | 0.37 | 1.99 | 4.62 | Upgrade
|
| Other Non Operating Income (Expenses) | -22.21 | -20.71 | -21.49 | -17.44 | -0.36 | -0.28 | Upgrade
|
| EBT Excluding Unusual Items | -111.34 | -98.32 | -108.03 | -109.37 | -118.51 | -105.15 | Upgrade
|
| Other Unusual Items | - | - | - | - | -6.6 | - | Upgrade
|
| Pretax Income | -111.34 | -98.32 | -108.03 | -109.37 | -125.11 | -105.15 | Upgrade
|
| Income Tax Expense | 4.04 | 3.92 | 1.76 | 1.45 | 3.37 | - | Upgrade
|
| Net Income | -115.38 | -102.24 | -109.78 | -110.82 | -128.48 | -105.15 | Upgrade
|
| Net Income to Common | -115.38 | -102.24 | -109.78 | -110.82 | -128.48 | -105.15 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 29 | 23 | 22 | 22 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 37 | 29 | 23 | 22 | 22 | 21 | Upgrade
|
| Shares Change (YoY) | 46.48% | 26.43% | 2.06% | 2.60% | 6.10% | 30.31% | Upgrade
|
| EPS (Basic) | -3.08 | -3.55 | -4.81 | -4.96 | -5.90 | -5.12 | Upgrade
|
| EPS (Diluted) | -3.08 | -3.55 | -4.81 | -4.96 | -5.90 | -5.12 | Upgrade
|
| Free Cash Flow | -96.38 | -76.57 | -87.81 | -85.64 | -107.1 | -71.34 | Upgrade
|
| Free Cash Flow Per Share | -2.58 | -2.66 | -3.85 | -3.83 | -4.92 | -3.48 | Upgrade
|
| Gross Margin | 90.27% | 88.68% | 88.11% | 89.27% | 91.45% | 100.00% | Upgrade
|
| Operating Margin | -93.70% | -79.23% | -122.82% | -192.11% | -1018.21% | -608211.11% | Upgrade
|
| Profit Margin | -129.11% | -123.61% | -170.58% | -230.67% | -1088.94% | -584144.44% | Upgrade
|
| Free Cash Flow Margin | -107.85% | -92.57% | -136.45% | -178.27% | -907.71% | -396344.44% | Upgrade
|
| EBITDA | -83.28 | -64.73 | -78.12 | -91.46 | -119.72 | -109.18 | Upgrade
|
| EBITDA Margin | -93.20% | -78.26% | -121.38% | -190.38% | - | - | Upgrade
|
| D&A For EBITDA | 0.45 | 0.8 | 0.92 | 0.83 | 0.42 | 0.3 | Upgrade
|
| EBIT | -83.73 | -65.54 | -79.04 | -92.29 | -120.14 | -109.48 | Upgrade
|
| EBIT Margin | -93.70% | -79.23% | -122.82% | -192.11% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.